Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) as part of lung-sparing multimodality therapy in patients with malignant pleural mesothelioma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Mesothelioma
  • Pleural Neoplasms
  • Radiation Pneumonitis
  • Radiotherapy, Intensity-Modulated

abstract

  • Hemithoracic IMPRINT for malignant pleural mesothelioma (MPM) is safe and has an acceptable rate of RP. Its incorporation with chemotherapy and P/D forms a new lung-sparing treatment paradigm for patients with locally advanced MPM.

publication date

  • August 10, 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5019761

Digital Object Identifier (DOI)

  • 10.1200/JCO.2016.67.2675

PubMed ID

  • 27325859

Additional Document Info

start page

  • 2761

end page

  • 8

volume

  • 34

number

  • 23